Rebecca Brooks, MD
Gynecologic Oncology · Sacramento, CANPI 1316155781
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $104,040 of the $133,371 with a category attached, or 78.0%. AstraZeneca accounts for 60.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $35,505, 2.9 times the $12,192 reported in 2019. Among gynecologic oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $1307.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$80K
- GSK$47K
- Eisai Inc.$3K
- Clovis Oncology, Inc.$2K
- AbbVie$333
- Caris MPI, Inc.$137
- plus $197 from 5 others
Across 9 payments — averaging $32,953 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$297K
What the payments were for
- Consulting fees$16,46812%
- Speaking & faculty fees$104,04078%
- Travel & lodging$9,0287%
- Food & beverage$3,7073%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $80,261 |
| GSK | 36 | $47,482 |
| Eisai Inc. | 1 | $2,740 |
| Clovis Oncology, Inc. | 4 | $2,222 |
| AbbVie | 3 | $333 |
| Caris MPI, Inc. | 1 | $137 |
| Tesaro, Inc. | 1 | $125 |
| Johnson & Johnson | 2 | $31 |
| Dysis Medical, Inc. | 1 | $15 |
| Medical Device Business Services, Inc. | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,371 in reported general payments places this provider in the 95th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 14 | $889 |
| Prochlorperazine Maleate | 11 | $126 |
| Ondansetron Hcl | 17 | $118 |
| Dexamethasone | 20 | $105 |
| Letrozole | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Sacramento
- Amanda Shepherd-LittlejohnSacramento$73K
- Melissa PhamSacramento$50K
- Alireza AbidiSacramento$13K
- Edwin AlvarezSacramento$12K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.